Ligand Pharmaceuticals
LGND | NASDAQ
$293.19
+$3.12 (+1.08%)
Sep 22, 2026, 11:19 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 29.36 | -487.05 | 23.65 | -33.74 | 27.85 | -344.67 |
PEG Ratio | -0.01 | 4.54 | -0.09 | 0.21 | -0.01 | 3.43 |
PS Ratio | 13.64 | 11.73 | 9.41 | 5.74 | 6.63 | 6.14 |
PB Ratio | 3.59 | 2.36 | 1.76 | 1.89 | 1.95 | 1.42 |
P/FCF Ratio | 74.76 | 25.32 | -289.19 | 9.40 | 22.88 | 20.03 |
P/OCF Ratio | 74.07 | 20.19 | 24.92 | 8.17 | 20.34 | 18.40 |
OCF/S Ratio | 18.41 | 58.07 | 37.75 | 70.24 | 32.62 | 33.37 |
Debt / Equity Ratio | 0.44 | 0.01 | 0.01 | 0.15 | 0.40 | 0.64 |
Quick Ratio | 21.98 | 8.55 | 12.72 | 2.53 | 10.50 | 4.74 |
Current Ratio | 22.23 | 8.93 | 14.15 | 2.67 | 11.15 | 5 |
Asset Turnover | 0.17 | 0.18 | 0.17 | 0.26 | 0.19 | 0.12 |
Interest Coverage | 10.01 | -7.44 | 18.20 | 1.69 | 5.29 | 1.37 |
Return on Equity | 12.23% | -0.49% | 7.44% | -5.58% | 6.96% | -0.42% |
Return on Assets | 7.97% | -0.43% | 6.63% | -4.37% | 4.40% | -0.22% |
Return on Invested Capital | 2.42% | 4% | 1.31% | -0.06% | 8.26% | 2.95% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 97.54% | 93.37% | 73.31% | 73.08% | 74.26% | 81.40% |
Net Profit Margin | 46.42% | -2.41% | 39.72% | -17% | 23.66% | -1.82% |
Pretax Profit Margin | 59.29% | 1.51% | 48.48% | 18.35% | 29.89% | 0.79% |
Operating Profit Margin | 17.61% | -13.53% | 9.09% | 1.55% | 42.99% | 22.93% |
FCF Margin | 18.24% | 46.31% | -3.25% | 61.11% | 29% | 30.65% |
EBITDA Margin | 71.89% | 24.41% | 76.79% | 41.38% | 59.11% | 34.65% |
Add to Watchlist
Select watchlists to add or remove LGND